HOIPIN-8
目录号 : GC63004
HOIPIN-8 是一种高效的线性泛素链组装复合体(LUBAC)的抑制剂,其IC50为11nM。
Sample solution is provided at 25 µL, 10mM.
HOIPIN-8 is a potent inhibitor of the linear ubiquitin chain assembly complex (LUBAC) with an IC₅₀ of 11nM [1]. LUBAC is an E3 ubiquitin ligase complex that specifically generates M1-linked linear polyubiquitin chains. It is composed of HOIL-1L, HOIP, and SHARPIN. LUBAC activates the NF-κB pathway and inhibits apoptosis via the linear ubiquitination of various substrates[2].
HOIPIN-8 (30μM) treatment of A431, MCF-7, and MDA-MB-231 cancer cells for 2h reduced the phosphorylation levels of both IκBα and p65 compared with the DMSO-treated group, along with a significant decrease in cell proliferation rates, demonstrating HOIPIN-8's ability to inhibit both NF-κB pathway activation and cancer cell proliferation[3]. Similarly, treatment with HOIPIN-8 (100μM) for 48h significantly reduced both proliferation rates and invasive capabilities in HepG2 and Hep3B cancer cell lines[4]. The TDP-43 A315T mutation, associated with amyotrophic lateral sclerosis (ALS), enhances TDP-43 protein aggregation. In Neuro2a cells expressing TDP-43 A315T247-414-GFP, treatment with HOIPIN-8(10μM) for 20h significantly reduced protein aggregation compared to untreated controls[5].
HOIPIN-8 (30μM) treatment of human pancreatic organoids (hPOs) for 30min effectively delayed BV6-induced organoid disintegration, prevented luminal structure collapse, and extended survival duration[6].
References:
[1] Katsuya K, Oikawa D, Iio K, et al., Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF-κB signaling, Biochemical and Biophysical Research Communications[J]. 2019, 509: 700-706.
[2] Tokunaga F, Iwai K, LUBAC, a novel ubiquitin ligase for linear ubiquitination, is crucial for inflammation and immune responses, Microbes and Infection[J]. 2012, 14: 563-572.
[3] Hua F, Hao W, Wang L, et al., Linear Ubiquitination Mediates EGFR-Induced NF-κB Pathway and Tumor Development, Int J Mol Sci[J]. 2021, 22: 11875.
[4] Hoshino K, Nakazawa S, Yokobori T, et al., RNF31 promotes proliferation and invasion of hepatocellular carcinoma via nuclear factor kappaB activation, Scientific Reports[J]. 2024, 14: 346.
[5] Zhang Q, Terawaki S, Oikawa D, et al., Suppression of Linear Ubiquitination Ameliorates Cytoplasmic Aggregation of Truncated TDP-43, Cells[J]. 2022, 11: 2398.
[6] Weinelt N, Wächtershäuser K N, Celik G, et al., LUBAC-mediated M1 Ub regulates necroptosis by segregating the cellular distribution of active MLKL, Cell Death & Disease[J]. 2024, 15: 77.
HOIPIN-8是一种高效的线性泛素链组装复合体(LUBAC)的抑制剂,其IC50为11nM[1]。LUBAC是一种E3泛素连接酶复合体,能够特异性催化M1连接的线性多聚泛素链的形成。该复合体由HOIL-1L、HOIP和SHARPIN组成。LUBAC通过对多种底物进行线性泛素化来激活 NF-κB 信号通路,并抑制细胞凋亡[2]。
HOIPIN-8(30μM)处理A431, MCF-7, and MDA-MB-231癌细胞2h,与DMSO处理组相比,IκBɑ以及p65的磷酸化水平下降,同时细胞增殖速率明显下降,表明HOIPIN-8能够抑制NF-κB通路的激活以及癌细胞增殖[3]。类似地,HOIPIN-8(100μM)处理HepG2和Hep3B癌细胞48小时,癌细胞增殖速率和侵袭能力明显下降[4]。TDP-43 A315T突变是一种和肌萎缩侧索硬化(ALS)相关的突变,它能够使得TDP-43蛋白聚集增加。在Neuro2a细胞中表达TDP-43 A315T247-414-GFP,使用HOIPIN-8(10μM)处理细胞20h,和未处理细胞相比,蛋白的聚集明显减少[5]。
HOIPIN-8(30μM)处理人类胰腺类器官(hPOs)30min,可以有效延缓BV6诱导的类器官崩溃,防止腔体形态的丧失,延长hPOs的存活时间[6]。
Cell experiment [1]: | |
Cell lines | A431, MCF-7, and MDA-MB-231 cancer cells |
Preparation Method | Cells were seeded in a 96-well plate at a density of 400 cells/well in 100μL culture medium. Then, cells were treated with DMSO or 30μM HOIPIN-8 for 2h. Cell growth rate was determined by the MTT Cell Proliferation Kit. |
Reaction Conditions | 30μM; 2h |
Applications | HOIPIN-8 significantly inhibited cell proliferation of A431, MCF-7, and MDA-MB-231 cancer cells. |
References: |
Cas No. | SDF | ||
分子式 | C23H15F2N4NaO3 | 分子量 | 456.38 |
溶解度 | DMSO : 100 mg/mL (219.12 mM; Need ultrasonic) | 储存条件 | Store at -20°C,protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.1912 mL | 10.9558 mL | 21.9116 mL |
5 mM | 0.4382 mL | 2.1912 mL | 4.3823 mL |
10 mM | 0.2191 mL | 1.0956 mL | 2.1912 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet